Pharmaceuticals, Biotechnology and Life Sciences
Novartis announced today that Susanne Schaffert, Ph.D., currently President, Advanced Accelerator Applications (AAA), a Novartis company, has been appointed CEO Novartis Oncology, and will join the Executive Committee in the beginning of new year. Liz Barrett will be stepping down as CEO of Novartis Oncology.
GenomOncology, a technology solution provider for oncology, named Brad Wertz as the new Chairman and Chief Executive Officer (CEO), who’ll assume the position from the start of year 2019. Wertz has been a founding investor and chairman of the board since the beginning, and has increased his involvement as the company has grown over the past two years.
AstraZeneca and Merck’s work on Lynparza is looking at mroe financial return after the US Food and Drug Administration (FDA) approved it for for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer.
Japan-based Fuji Pharma has acquired a 4.2% stake in the biopharmaceutical company Alvotech for around $50 million.
Mereo BioPharma on Tuesday presented positive data after testing BGS-649, oral inhibitor aromatase treatment of hypogonadotropic hypogonadism (HH) for obese…
Verona Pharma started the second phase of clinically evaluating a dry powder inhaler (DPI) formulation of RPL554 in moderate to…
Alvogen’s Chairman & CEO Robert Wessman is the new Chairman of the Board at the publicly listed Lotus Pharmaceuticals in Taiwan, succeeding Andrew Lin. Lotus Pharmaceuticals, which is majority-owned by Alvogen, has been under the leadership and guidance of Lin since 2016.
MyCartis said Thursday it will engage in a novel point-of-need diagnostic solution named Antelope Dx, in its strategy to innovate novel immunodiagnostic technologies.
In the world of great discoveries that cure or add a positive element to our everyday existence, the invention of microbeads hasn’t proven to be one of them. Not alone in its quick rise to popularity and slow journey to extinction, the microbead is just one of numerous products rushed to market before its long term effects are uncovered.
Denali Therapeutics has started dosing Parkinson’s disease patients with its therapeutic candidate for slowing the progression of disease, in a…